Aju IB Investment

Total investments

129

Average round size

16M

Portfolio companies

106

Rounds per year

2.58

Lead investments

5

Follow on index

0.17

Exits

13

Stages of investment
Late Stage Venture
Areas of investment
BiotechnologyE-CommerceSoftwareInformation TechnologyHealth CareHealth DiagnosticsMedicalLife SciencePharmaceuticalTherapeutics

Summary

Aju IB Investment is the famous Corporate Investor, which was founded in 1974. The venture was found in Asia in South Korea. The main department of described Corporate Investor is located in the Yeoksamdong.

Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Synlogic, Tibit Communications, Kymera Therapeutics We can highlight the next thriving fund investment areas, such as Pharmaceutical, Biopharma. The fund has exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.

The fund is constantly included in less than 2 investment rounds annually. The top activity for fund was in 2019. The increased amount of exits for fund were in 2017. Considering the real fund results, this Corporate Investor is 9 percentage points less often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. Comparing to the other companies, this Aju IB Investment performs on 18 percentage points more the average number of lead investments.

The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the Aju IB Investment, startups are often financed by Hatteras Venture Partners, Excel Venture Management, Lilly Ventures. The meaningful sponsors for the fund in investment in the same round are Cormorant Asset Management, Hatteras Venture Partners, Rock Springs Capital. In the next rounds fund is usually obtained by Cormorant Asset Management, venBio Partners, Morningside Group.

The overall number of key employees were 4.

Show more

Investments analytics

Analytics

Total investments
129
Lead investments
5
Exits
13
Rounds per year
2.58
Follow on index
0.17
Investments by industry
  • Biotechnology (41)
  • Health Care (35)
  • Therapeutics (23)
  • Pharmaceutical (17)
  • Medical (17)
  • Show 124 more
Investments by region
  • South Korea (99)
  • United States (23)
  • India (1)
  • Japan (1)
Peak activity year
2021
Number of Unicorns
1
Number of Decacorns
1
Number of Minotaurs
2

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
8
Avg. valuation at time of investment
79M
Group Appearance index
0.95
Avg. company exit year
9
Strategy success index
0.60

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Cenyx Biotech 30 Apr 2021 Health Diagnostics, Therapeutics, Nanotechnology Early Stage Venture 16M Seoul, Seoul-t'ukpyolsi, South Korea
DEEPX 09 May 2024 Late Stage Venture 80M Kyonggi-do, Seongnam, South Korea

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.